Trichomylin for Cancer Pain
(UTOPIA-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness and safety of a new treatment called Trichomylin® for managing pain in people with advanced cancer. Trichomylin® is a capsule containing a mix of compounds that may help relieve pain. The trial seeks participants with advanced solid tumors who experience moderate to severe pain despite using opioids for at least a week. Those with consistent cancer-related pain and openness to a treatment with potential psychoactive effects may find this trial suitable. As a Phase 2 trial, this research measures how well Trichomylin® works in an initial, smaller group, offering participants a chance to contribute to important findings.
Do I have to stop taking my current medications for the trial?
You can continue taking your current opioid medication, but you must stop using certain herbal supplements and products like grapefruit juice and St. John's wort 7 days before the trial starts. You also need to avoid any cannabis products for 30 days before the trial and during the study.
Is there any evidence suggesting that Trichomylin® is likely to be safe for humans?
Research has shown that Trichomylin®, which contains cannabinoids (natural compounds from cannabis), has been studied for its safety in managing cancer pain. One study found that a THC:CBD extract, similar to Trichomylin®, relieved pain in patients with advanced cancer whose pain wasn't fully controlled by strong painkillers. This suggests these compounds can be safe for such patients.
Another review of medical cannabis for cancer pain found it can reduce chronic pain in advanced cancer patients. While these studies support the safety of treatments like Trichomylin®, some patients may experience side effects, such as dizziness or dry mouth, which are common with cannabinoid use.
This trial is a Phase 2 study, aiming to further test the safety and effectiveness of Trichomylin®. Earlier research has shown promise, but more data is needed to confirm its safety for wider use.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for cancer pain, which often rely on opioids and other pharmaceuticals, Trichomylin® is unique because it harnesses the power of cannabinoids, specifically delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabichromene (CBC). This combination of cannabinoids targets pain through multiple pathways, potentially offering a more comprehensive pain management solution with fewer side effects. Researchers are excited about Trichomylin® because it represents a shift towards using natural compounds to manage cancer pain, which could improve patients' quality of life by reducing reliance on traditional painkillers.
What evidence suggests that Trichomylin® might be an effective treatment for cancer pain?
Research has shown that cannabinoids, like those in Trichomylin, have produced mixed results in relieving cancer pain. One study found that cannabinoids did not reduce cancer pain. However, some components of Trichomylin, such as cannabichromene, demonstrated strong effects against cancer cells in lab tests. Another study found some pain relief with a different cannabinoid formula. While cannabinoids show promise, the effectiveness of Trichomylin for cancer pain remains under investigation in this trial.16789
Who Is on the Research Team?
Julie Stakiw, MD
Principal Investigator
Saskatoon Cancer Centre
Are You a Good Fit for This Trial?
This trial is for adults with advanced cancer who have moderate to severe pain despite taking stable long-acting opioids. They should expect to live at least 3 more months, have normal blood electrolytes, stable kidney function, and acceptable liver enzyme levels. People with significant heart abnormalities or those whose cancer can still be cured by surgery are not eligible.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Titration
Participants undergo a titration phase to determine the optimal dose of Trichomylin® for symptom relief with tolerable side effects
Stable Dose Assessment
Participants are assessed for 5 days at the stable dose determined during titration
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Trichomylin®
Find a Clinic Near You
Who Is Running the Clinical Trial?
ZYUS Life Sciences Inc.
Lead Sponsor